Beijing Berry and Kang Biotechnology Co., Ltd. (hereinafter referred to as Berry Gene) was established in May 2010. It is committed to applying high-throughput gene sequencing technology to provide a “non-invasive” overall solution for clinical medical disease screening and diagnosis. The research and development biotechnology company is the industry leader in clinical transformation of gene sequencing technology. Berry's R&D team is led by Dr. Gao Yang and Dr. Zhou Xingxing, who was involved in the design and development of high-throughput sequencers. He is composed of top-notch experimental, R&D and bioinformatics experts in the field of high-throughput sequencing and clinical genetic testing. And established a cooperative relationship with world-renowned research institutions in the field. Berry Gene has become the world's leading research center for high-throughput sequencing technology and applications. The company was awarded the Zhongguancun High-tech Enterprise Certification in September 2011, the National High-tech Enterprise Certification in December 2012, and successfully listed on the A-share Main Board in August 2017. Under the background of the promotion of biomedicine to “National Strategic Emerging Industries”, Berry Genetics is the first to implement human genome sequencing technology in clinical testing with its core technology. In the field of screening and diagnosis of congenital genetic diseases, Berry has developed a comprehensive set of independent intellectual property rights for the "non-invasive DNA prenatal testing" technology (abbreviated as Bebean), the first non-invasive production of fetal chromosomal diseases. Pre-test. Subsequently, it can be used for pre-pregnancy, prenatal and pre-pregnancy and genetic disease probands of the Konoan chromosome disease test (referred to as Konoan), can be used to assist the reproductive technology in the pre-implantation chromosome number and structural abnormalities of the pregnant women embryo implantation The pre-immune genetic screening (referred to as Keyong'an) testing has been successively launched, further enriching and perfecting the detection technology system for genetic disease screening and diagnosis. On this basis, Berry and Kang have developed a detection technology for non-invasive fetal microdeletion microrepetition and non-invasive fetal single gene disease genotyping, in order to achieve safe, accurate, efficient and full coverage of clinical genetic disease screening. Check and diagnose new modes. While continuing to deepen the field of genetic disease screening and diagnosis, Berry has successfully launched the internationally leading Onconi tumor molecular diagnostic product based on high-throughput sequencing technology in the field of tumor molecular diagnosis, involving targeted drug use. Detection, efficacy monitoring, medication monitoring, tumor susceptibility testing, tumor individualized medical comprehensive testing, to achieve the overall coverage of tumor molecular detection. The detection of non-invasive tumor genes with cSMART technology with independent intellectual property rights has opened up a new model for clinical practice. In addition, the data accumulated by Berry Gene in prenatal testing, pre-pregnancy testing, genetic disease testing, and tumor detection has been constructed as a large genome database with Chinese characteristics. By collaborating with leading international institutions such as Baylor College of Medicine and Alibaba Cloud, Berry will use cloud storage and cloud computing platforms to realize the most simplified terminal applications and real-time sharing of genomic data. At this point, the Berry gene has formed a deeper level of technical dimensions from the number of chromosomes and the level of structure, the microdeletion level of chromosome microdeletions, and the level of genes; from the product dimensions of pre-marital, pre-pregnancy, pre-natal, neonatal, and cancer; The individual genomic data is interpreted into the three-dimensional development structure of the population genomic data analysis, and then to the digitized dimension of the instructional individual genomic data interpretation. In March 2015, the State Food and Drug Administration (CFDA) approved the genetic sequencer (NextSeq CN500) produced by Hangzhou Berry and Kang Gene Diagnostic Technology Co., Ltd., as well as fetal chromosome aneuploidy (T13/T18/T21). The detection kit (reversible end-stop sequencing) medical device product registration marks Berry and Kang's successful layout of the genetic testing upstream industry. With the completion of these projects, Berry Gene has developed into an industrial structure based in Beijing covering Shanghai, Qingdao, Chengdu, Changsha, Hangzhou and other medical research institutes and Hangzhou production bases, and Professor Lu Yuming in Hong Kong and the Chinese University of Hong Kong. Cooperate to establish Hong Kong Ysengeng Gene Technology Co., Ltd. (Xcelom), which provides a more secure genetic testing service for Hong Kong and surrounding areas through the patent authorization of the Chinese University of Hong Kong. The market network covers more than 2,000 hospitals in more than 30 provinces, municipalities and autonomous regions in China. It has a high standard of R&D, marketing, sales, customer service and other systems. There are more than 1,400 employees. With the successful listing of the A-share main board in 2017, it is worthy of the name. Become a leader in the genetic testing industry.